Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.53 |
| ▸ | GSK3A | P49840 | 8/20 | 0.53 |
| ▸ | AURKA | O14965 | 9/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579319 | 0.92 | GSK3B (0.50) | GSK3BGSK3AAURKAAURKBPLA2G10 | |
| SCHEMBL1353745 | 0.85 | AURKA (0.53) | GSK3BGSK3AAURKAAURKBJAK2 | |
| SCHEMBL3591261 | 0.85 | GSK3A (0.39) | GSK3BGSK3AAURKA | |
| SCHEMBL3583178 | 0.84 | SRC (0.42) | GSK3BGSK3AEGFR | |
| SCHEMBL3581129 | 0.83 | CDK4 (0.39) | GSK3BGSK3AAURKAEGFRPOLB | |
| SCHEMBL3581123 | 0.81 | CDK4 (0.44) | GSK3BGSK3A | |
| SCHEMBL3588646 | 0.81 | CDK4 (0.39) | GSK3BGSK3AAURKAEGFR | |
| SCHEMBL3588854 | 0.80 | PDGFRB (0.47) | KDRPOLB | |
| SCHEMBL3588642 | 0.80 | JAK1 (0.41) | JAK2POLB | |
| SCHEMBL3573049 | 0.80 | CDK1 (0.46) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | GSK3B 116/4885GSK3A 129/4885AURKA 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.